Key result
Gut microbiome Cluster L linked to ~52% lower MACE risk versus Cluster H.
Why the study?
The potential of the gut microbiome as a biomarker for risk stratification in patients with atherosclerotic cardiovascular comorbidities remains underexplored.
Is a specific gut microbiome compositional cluster associated with a reduced risk of Major Adverse Cardiac Events in patients with cardiovascular comorbidities?
Is a specific gut microbiome compositional cluster associated with a reduced risk of Major Adverse Cardiac Events in patients with cardiovascular comorbidities?
Distinct gut microbiome profiles identified via unsupervised clustering are significantly associated with long-term major adverse cardiac events, suggesting potential for novel risk stratification.
Answers are grounded in this paper and cite their sources.
Cluster L microbiome profile was associated with lower MACE; hypothesis-generating for risk stratification, prospective trials needed.
Aims The gut microbiome (GM) is increasingly recognized for its role in atherosclerosis development. However, its potential as a biomarker for risk-stratification in patients with atherosclerotic cardiovascular (CV) comorbidities remains under-explored. This study aimed to identify distinct GM clusters associated with elevated CV risk. Methods In this prospective observational cohort, patients with coronary artery disease, hypertension, hyperlipidemia, or diabetes mellitus referring to Mayo Clinic from 2013 to 2018 were enrolled. Bacterial DNA was analyzed in the V3-V5 region of 16S rDNA. Beta-diversity was plotted using Principal Coordinates Analysis. Unsupervised hierarchical clustering of the GM classified participants into two clusters. Cox regression evaluated the association between clusters and Major Adverse Cardiac Events (MACE), defined as a composite of cardiac events, heart failure, and all-cause mortality. Permutational Multivariate Analysis of Variance identified clinical factors contributing to cluster assignment. Linear Discriminant analysis identified GM taxa with differential abundance among clusters and their effect sizes. Results Among 211 participants (median age 60 [IQR: 50–70] years; 57.3% male), two distinct GM profiles emerged (Cluster H: N = 104; Cluster L: N = 107, P < 0.001). Cluster L participants were younger (P < 0.001), more likely female (P = 0.009), and had healthier CV profiles, including lower BMI (P = 0.007), hypertension (P = 0.010), hyperlipidemia (P = 0.005), and lower coronary artery disease prevalence (P = 0.003). Over a median follow-up of 7.4 years, Cluster L had a significantly lower incidence of MACE compared to Cluster H (HR = 0.48, 95% CI: 0.26–0.91, P = 0.024). Cluster L had higher operational taxonomic units (P < 0.001) and lower Bacillota-to-Bacteroidetes ratio (P < 0.001) compared to Cluster H. The predominant taxa in Cluster L included Bacteroides , Alistipes , and Parabacteroides , whereas Blautia , Agathobacter , and Clostridium sensu stricto-1 were more abundant in Cluster H. Conclusion Distinct GM profiles are associated with varying CV risk, highlighting the potential of unsupervised GM profiling as a novel tool for risk stratification and individualized therapy.
No takes yet. Share an insight, caveat, or question.
Hamidabad et al. (2026) studied this question. Patients with distinct gut microbiome Cluster L had a 52% lower risk of major adverse cardiac events over 7.4 years versus Cluster H (HR 0.48, P=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: